Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation
Yan L, Bui D, Li Y, Rajeevan N, Rowneki M, Berry K, Argraves S, Huang Y, Hynes D, Cunningham F, Huang G, Aslan M, Ioannou G, Bajema K. Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation. Clinical Infectious Diseases 2024, 79: 643-651. PMID: 38864601, DOI: 10.1093/cid/ciae202.Peer-Reviewed Original ResearchRisk quartileVeterans Health AdministrationLowest risk quartileHighest risk quartileTarget trial emulationRisk prediction modelUntreated veteransRisk of deathOlder veteransYounger veteransHealth AdministrationTrial emulationMeasure incidenceNirmatrelvir-ritonavirVeteransHospitalUntreated participantsCOVID-19QuartileRiskSevere coronavirus disease 2019ParticipantsPersonsCoronavirus disease 2019Severe COVID-19